UROTENSIN-II AS A PROMISING KEY-POINTS OF CARDIOVASCUAL DISTURBANCES SEQUAL

[1]  Hongli Li,et al.  Urotensin II induces activation of NLRP3 and pyroptosis through calcineurin in cardiomyocytes , 2021, Peptides.

[2]  Ai-hua Zhang,et al.  Expression of urotensin II is positively correlated with pyroptosis-related molecules in patients with severe preeclampsia , 2020, Clinical and experimental hypertension.

[3]  A. Koçyiğit,et al.  Urotensin-II, oxidative stress, and inflammation increase in hypertensive and resistant hypertensive patients , 2020, Clinical and experimental hypertension.

[4]  L. Bahar,et al.  Role of Urotensin-II in Saphenous Vein Graft Disease , 2020, Brazilian journal of cardiovascular surgery.

[5]  S. Marumoto,et al.  Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice. , 2020, European journal of pharmacology.

[6]  F. Barbe,et al.  Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[7]  F. Ozdemir,et al.  An Investigation of Saliva and Plasma Levels of Urotensin-2 in Recently Diagnosed Type 2 Diabetes Mellitus Patients on Metformin Treatment. , 2020, Endokrynologia Polska.

[8]  Guang-xin Miao,et al.  Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats. , 2020, Life sciences.

[9]  S. Marumoto,et al.  The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure , 2020, Heliyon.

[10]  Chien-Sung Tsai,et al.  Functional effects of urotensin-II on intracellular pH regulators in human radial artery smooth muscle cells , 2019, Peptides.

[11]  Rong Wang,et al.  Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits , 2019, Acta Pharmacologica Sinica.

[12]  Y. Uyanikgil,et al.  Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats. , 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[13]  Retraction: Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS , 2019, PloS one.

[14]  M. Vernero,et al.  Is urotensin II a new inflammatory marker of inflammatory bowel disease? , 2019, Minerva gastroenterologica e dietologica.

[15]  G. Du,et al.  Chronic Urotensin-II Administration Improves Whole-Body Glucose Tolerance in High-Fat Diet-Fed Mice , 2019, Front. Endocrinol..

[16]  E. Novellino,et al.  Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides. , 2019, Journal of medicinal chemistry.

[17]  L. Liu,et al.  Urotensin II: an inflammatory cytokine. , 2019, The Journal of endocrinology.

[18]  Guangli Xu,et al.  Urotensin-II gene rs228648 polymorphism associated with the risk of diabetes mellitus , 2018, Bioscience reports.

[19]  R. Cecere,et al.  UROTENSIN II, UROTENSIN-RELATED PEPTIDE AND THEIR RECEPTOR IN AORTIC VALVE STENOSIS , 2018, Canadian Journal of Cardiology.

[20]  A. Bilici,et al.  Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients , 2018, Oncology Research and Treatment.

[21]  Po-Yuan Chen,et al.  Cafestol, a coffee diterpene, inhibits urotensin II‐induced interleukin‐8 expression in human umbilical vein endothelial cells , 2018, European journal of pharmacology.

[22]  G. Aliev,et al.  Urotensin II: Molecular Mechanisms of Biological Activity. , 2017, Current protein & peptide science.

[23]  Jun Li,et al.  Urotensin II promotes aldosterone expression in rat aortic adventitial fibroblasts , 2017, Molecular medicine reports.

[24]  A. Ahmed,et al.  Endothelin-1 and angiotensin-II modulate urotensin-II vasoconstriction in rat aorta exposed to mercury. , 2018, Bratislavske lekarske listy.

[25]  K. Yi,et al.  A novel urotensin II receptor antagonist, KR‐36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure , 2017, European journal of pharmacology.

[26]  E. Novellino,et al.  Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. , 2017, Current cancer drug targets.

[27]  I. Elmadbouh,et al.  The value of urotensin II in patients with left-sided rheumatic valvular regurgitation , 2016, The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology.

[28]  M. Çetin,et al.  The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow , 2016, Interventional medicine & applied science.

[29]  K. Yi,et al.  Blockade of Urotensin II Receptor Prevents Vascular Dysfunction , 2016, Biomolecules & therapeutics.

[30]  S. Daskalopoulou,et al.  The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification , 2016, Front. Pharmacol..

[31]  Sheng-Yong Luo,et al.  Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway , 2016, PloS one.

[32]  H. Korkmaz,et al.  Urotensin-II level and its association with oxidative stress in early diabetic nephropathy. , 2015, Journal of diabetes and its complications.

[33]  Yen-Ling Chen,et al.  Urotensin II Inhibits Doxorubicin-Induced Human Umbilical Vein Endothelial Cell Death by Modulating ATF Expression and via the ERK and Akt Pathway , 2014, PloS one.

[34]  Yanli Wang,et al.  Urotensin II Promotes Atherosclerosis in Cholesterol-Fed Rabbits , 2014, PloS one.

[35]  N. Ashton,et al.  The Urotensin System Is Up-Regulated in the Pre-Hypertensive Spontaneously Hypertensive Rat , 2013, PloS one.

[36]  J. Egea-Guerrero,et al.  Contractile responses to rat urotensin II in resting and depolarized basilar arteries , 2013, Journal of Physiology and Biochemistry.

[37]  K. Soylu,et al.  Serum Urotensin II Levels in Patients with Non-Dipper Hypertension , 2013, Clinical and experimental hypertension.

[38]  Bo Sun,et al.  The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats , 2013, Experimental and therapeutic medicine.

[39]  M. Dal,et al.  Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[40]  D. Kelly,et al.  Urotensin II and the kidney , 2013, Current opinion in nephrology and hypertension.

[41]  Jing Zhao,et al.  Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB–5-LO pathway by p38 MAPK and ERK activations , 2013, Heart and Vessels.

[42]  Yen-Ling Chen,et al.  Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. , 2012, European journal of pharmacology.

[43]  Y. Nie,et al.  Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway , 2012, Molecular and Cellular Biochemistry.

[44]  Wei-Jan Chen,et al.  Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast , 2012, European journal of clinical investigation.

[45]  R. S. Kiss,et al.  Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis , 2011, Peptides.

[46]  Jérôme Leprince,et al.  Urotensin II, from fish to human , 2010, Annals of the New York Academy of Sciences.

[47]  D. Guidolin,et al.  Urotensin-II as an angiogenic factor , 2010, Peptides.

[48]  B. Maryanoff,et al.  Urotensin-II receptor modulators as potential drugs. , 2010, Journal of medicinal chemistry.

[49]  Y. Imai,et al.  The renin–angiotensin system, adrenomedullins and urotensin II in the kidney: Possible renoprotection via the kidney peptide systems , 2009, Peptides.

[50]  A. Miyazaki,et al.  Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. , 2009, Current medicinal chemistry.